{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["31(11)"],"submitter":["Sun CP"],"pubmed_abstract":["The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the emergence of new variants that are resistant to existing vaccines and therapeutic antibodies, has raised the need for novel strategies to combat the persistent global COVID-19 epidemic. In this study, a monoclonal anti-human angiotensin-converting enzyme 2 (hACE2) antibody, ch2H2, was isolated and humanized to block the viral receptor-binding domain (RBD) binding to hACE2, the major entry receptor of SARS-CoV-2. This antibody targets the RBD-binding site on the N terminus of hACE2 and has a high binding affinity to outcompete the RBD. In vitro, ch2H2 antibody showed potent inhibitory activity against multiple SARS-CoV-2 variants, including the most antigenically drifted and immune-evadin"],"journal":["Molecular therapy : the journal of the American Society of Gene Therapy"],"pagination":["3322-3336"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10638075"],"repository":["biostudies-literature"],"pubmed_title":["Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants."],"pmcid":["PMC10638075"],"pubmed_authors":["Chang CS","Ng HY","Chen LY","Liao CC","Kuo TJ","Chung MJ","Danny Hsu ST","Wu PY","Tsung SI","Tseng SC","Liu WC","Tao MH","Wu HC","Lo CH","Sun CP","Draczkowski P","Puri S","Hsu MF","Liang JJ","Chen CC","Hu CW","Liao HN","Huang JS","Lan YH","Chang YC","Chiu CW","Kau JH","Lee IJ","Chen YJ","Chen YH","Wang IH"],"additional_accession":[]},"is_claimable":false,"name":"Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants.","description":"The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the emergence of new variants that are resistant to existing vaccines and therapeutic antibodies, has raised the need for novel strategies to combat the persistent global COVID-19 epidemic. In this study, a monoclonal anti-human angiotensin-converting enzyme 2 (hACE2) antibody, ch2H2, was isolated and humanized to block the viral receptor-binding domain (RBD) binding to hACE2, the major entry receptor of SARS-CoV-2. This antibody targets the RBD-binding site on the N terminus of hACE2 and has a high binding affinity to outcompete the RBD. In vitro, ch2H2 antibody showed potent inhibitory activity against multiple SARS-CoV-2 variants, including the most antigenically drifted and immune-evadin","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2026-06-02T23:10:31.942Z","creation":"2025-04-04T00:26:31.41Z"},"accession":"S-EPMC10638075","cross_references":{"pubmed":["37689971"],"doi":["10.1016/j.ymthe.2023.09.002"]}}